- Home
- REAL vs NUVB Comparison
REAL vs NUVB Comparison
Compare REAL & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAL
- NUVB
- Stock Information
- Founded
- REAL 2011
- NUVB 2018
- Country
- REAL United States
- NUVB United States
- Employees
- REAL N/A
- NUVB N/A
- Industry
- REAL Other Specialty Stores
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- REAL Consumer Discretionary
- NUVB Health Care
- Exchange
- REAL Nasdaq
- NUVB Nasdaq
- Market Cap
- REAL 641.9M
- NUVB 679.9M
- IPO Year
- REAL 2019
- NUVB N/A
- Fundamental
- Price
- REAL $5.09
- NUVB $1.95
- Analyst Decision
- REAL Buy
- NUVB Strong Buy
- Analyst Count
- REAL 5
- NUVB 6
- Target Price
- REAL $8.40
- NUVB $7.83
- AVG Volume (30 Days)
- REAL 2.8M
- NUVB 7.6M
- Earning Date
- REAL 08-05-2025
- NUVB 08-04-2025
- Dividend Yield
- REAL N/A
- NUVB N/A
- EPS Growth
- REAL N/A
- NUVB N/A
- EPS
- REAL N/A
- NUVB N/A
- Revenue
- REAL $616,717,000.00
- NUVB $10,957,000.00
- Revenue This Year
- REAL $11.70
- NUVB $106.80
- Revenue Next Year
- REAL $10.10
- NUVB $320.63
- P/E Ratio
- REAL N/A
- NUVB N/A
- Revenue Growth
- REAL 11.89
- NUVB N/A
- 52 Week Low
- REAL $2.24
- NUVB $1.54
- 52 Week High
- REAL $11.38
- NUVB $3.97
- Technical
- Relative Strength Index (RSI)
- REAL 43.46
- NUVB 44.43
- Support Level
- REAL $5.02
- NUVB $1.58
- Resistance Level
- REAL $5.37
- NUVB $1.89
- Average True Range (ATR)
- REAL 0.32
- NUVB 0.23
- MACD
- REAL -0.04
- NUVB -0.06
- Stochastic Oscillator
- REAL 11.58
- NUVB 33.04
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).